ACADIA Pharmaceuticals Inc (ACAD)

Total asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	957,797	929,236	890,534	813,806	726,437	631,886	550,901	520,229	517,235	511,503	512,401	493,059	484,145	474,394	463,359	458,241	441,755	419,074	393,083	366,185
Total assets	US$ in thousands	1,187,760	976,868	914,099	855,103	748,956	632,540	642,769	655,305	587,812	602,491	612,766	624,251	700,122	717,673	724,429	755,173	782,616	795,664	759,649	747,450
Total asset turnover		0.81	0.95	0.97	0.95	0.97	1.00	0.86	0.79	0.88	0.85	0.84	0.79	0.69	0.66	0.64	0.61	0.56	0.53	0.52	0.49

December 31, 2024 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $957,797K ÷ $1,187,760K
= 0.81

The total asset turnover of ACADIA Pharmaceuticals Inc has shown a general increasing trend over the observed periods, reflecting the company's ability to generate revenue relative to its total assets. From March 31, 2020, to December 31, 2024, the total asset turnover ratio has increased steadily from 0.49 to 0.81, with some fluctuations along the way.

Notable points include a significant improvement in the total asset turnover ratio from September 30, 2022 (0.85) to September 30, 2023 (1.00) indicating a more efficient utilization of assets to generate sales during that quarter. However, by December 31, 2023, the ratio decreased slightly to 0.97 before dropping further to 0.81 by December 31, 2024.

Overall, the increasing trend in the total asset turnover ratio indicates an improved efficiency in generating revenue per dollar of assets over the analyzed period, although fluctuations in the ratio suggest varying levels of asset utilization efficiency and sales generation capabilities for ACADIA Pharmaceuticals Inc.